Concurrent Aumolertinib Plus Icotinib for First-Line Treatment of EGFR-Mutant NSCLC with CNS Metastases: A Prospective Phase I/II Study

被引：0

作者：

Huang, M. J. ^{[1
,2
]}

Yu, M. ^{[1
,2
]}

Gong, Y. L. ^{[2
,3
]}

Li, Y. Y. ^{[2
]}

Liu, Y. M. ^{[2
]}

Peng, F. ^{[2
]}

Yu, Y. ^{[2
]}

Xiu, W. G. ^{[2
]}

Wang, Y. S. ^{[2
,4
]}

Zou, B. W. ^{[2
]}

Fan, H. ^{[5
]}

Zhong, L. Q. ^{[6
]}

Liu, T. Q. ^{[7
]}

Wang, X. F. ^{[8
]}

Xu, Y. ^{[2
]}

Zhou, L. ^{[2
]}

Lu, Y. ^{[1
,3
,9
]}

机构：

[1] Sichuan Univ, West China Hosp, Div Thorac Tumor Multimodal Treatment, Ctr Canc, Chengdu, Peoples R China

[2] Sichuan Univ, West China Hosp, Dept Med Oncol, Ctr Canc, Chengdu, Peoples R China

[3] Sichuan Univ, West China Hosp, Dept Radiat Oncol, Ctr Canc, Chengdu, Peoples R China

[4] Sichuan Univ, West China Hosp, Dept Clin Res, Chengdu, Peoples R China

[5] Peoples Hosp Leshan, Leshan, Peoples R China

[6] Yibin Second Peoples Hosp, Yibin, Peoples R China

[7] Hosp Shimian Cty, Yaan, Peoples R China

[8] Sichuan Sci City Hosp, Chengdu, Peoples R China

[9] Sichuan Univ, West China Hosp, Lab Clin Cell Therapy, Chengdu, Peoples R China

来源：

JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期

关键词：

aumolertinib; icotinib; central nervous system metastases;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA13.05

引用

页码：S146 / S146

页数：1

共 50 条

[21] Efficacy of Chemotherapy after First-Line Gefitinib for EGFR-Mutant NSCLC Patients
Kuwako, Tomohito
Imai, Hisao
Masuda, Tomomi
Miura, Yosuke
Yoshino, Reiko
Kaira, Kyoichi
Shimizu, Kimihiro
Sunaga, Noriaki
Tomizawa, Yoshio
Ishihara, Shinichi
Mogi, Akira
Hisada, Takeshi
Minato, Koichi
Takise, Atsushi
Saito, Ryusei
Yamada, Masanobu
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S646 - S646
[22] First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC
Ricciuti, Biagio
Chiari, Rita
TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 : S127 - S130
[23] First-line aumolertinib in EGFR-mutant pulmonary adenosquamous carcinoma: Updated overall survival of the multicenter, single-arm, prospective study (ARISE)
Zhang, L. F.
Huang, L.
Huang, D.
Liu, Z.
Yu, Y.
Miao, K.
Miao, Q.
Zheng, X.
Xu, Y.
Chu, Q.
Lin, G.
ANNALS OF ONCOLOGY, 2024, 35
[24] Antacid and de novo brain metastases in EGFR-mutant NSCLC patients treated with first-line, first-generation EGFR-TKIs
Chen, Y-M.
Lin, M-C.
Lai, C-H.
Fang, W-F.
Chang, H-C.
Wang, C-C.
Tseng, C-C.
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S132 - S132
[25] Treatment Patterns and Clinical Outcomes in Patients with EGFR-mutant NSCLC after Progression on First-Line Osimertinib
Robinson, N. D.
Zhan, P.
Udelsman, B.
Boffa, D. J.
Goldberg, S. B.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S364 - S364
[26] EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC
Stock-Martineau, Sophie
Shepherd, Frances A.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (11) : 1793 - 1797
[27] Lifetime incidence of brain metastases (BM) in EGFR-mutant (M plus ) lung cancer treated with first-line EGFR TKIs
Ng, D. Z.
Tan, W. L.
Ong, W. S.
Gan, E. M.
Jain, A.
Tan, E. -H.
Tan, D.
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S117 - S117
[28] Aumolertinib plus chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 19 deletion or exon 21 L858R: a phase II trial
Li, Yanwei
Li, Chenguang
Zhao, Xiaoliang
Li, Yong
He, Feng
Pan, Zhanyu
ONCOLOGIST, 2025, 30 (03):
[29] Aumolertinib in Treatment-Naive EGFR-Mutant NSCLC Patients with Brain Metastases:Efficacy and Safety Data from the ARTISTRY
Zhang, X.
Zhang, M.
Wei, C.
Du, X.
Zhang, G.
Niu, Y.
Yan, X.
Yang, J.
Wang, H.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S194 - S194
[30] Real-World Study of First-Line Therapy with Aumolertinib for Elderly EGFR plus NSCLC Patients: The Updated Results
Fang, S.
Xu, T.
Zhao, X.
Liu, N.
Wang, X.
Cheng, W.
Fang, H.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S671 - S671

← 1 2 3 4 5 →